Vertex Pharmaceuticals (VRTX) stock analysis
A free, instant KC Score and technical read on Vertex Pharmaceuticals, from the last 12 months of price data.
Vertex Pharmaceuticals
Strong, established uptrend with positive momentum.
3-month +8.7%, 6-month +15.1%.
Price is above its 50-day and above its 200-day average; 50DMA above 200DMA.
Trading 8% below its 52-week high — 76% of the way up its yearly range.
Annualised volatility ~29% — moderately choppy.
The KC Score is a transparent 0–100 read of Vertex Pharmaceuticals's recent price behaviour, built from ~12 months of daily closing prices. Momentum weighs 3- and 6-month returns; Trend checks price against its 50- and 200-day moving averages; Range strength measures where it sits in its 52-week range; Stability reflects volatility. It is a descriptive technical summary — not a forecast, price target, or recommendation to buy or sell. Markets change daily; re-check before acting and do your own research.
What the KC Score says about Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) currently carries a KC Score of 82 out of 100 — a grade of A. In plain terms: strong, established uptrend with positive momentum. The score is a transparent, rules-based read of roughly the last twelve months of Vertex Pharmaceuticals's daily closing prices. It describes momentum, trend, range position and stability — it is not a buy or sell recommendation, and it knows nothing about Vertex Pharmaceuticals's valuation, earnings or news. At the last hourly update the stock traded near USD516.34, up 1.1% on the session, sitting 76% of the way up its 52-week range and about 7.8% below its 52-week high.
Momentum scores 67 out of 100. Over the past three months Vertex Pharmaceuticals has moved 8.7%, and 15.1% over six months — a broadly positive run that lifts the momentum reading. On trend (100/100), the price is above its 50-day moving average and above its 200-day average. Both averages sitting below the price is the classic shape of an established uptrend.
Range position scores 76/100: at 76% of its 52-week band, Vertex Pharmaceuticals is trading toward the top of where it has been over the last year. Stability scores 81/100, off annualised volatility of about 29% — moderate for a single stock. Lower volatility means steadier day-to-day movement, though it is never a guarantee against a large fall.
For a long-term investor, one stock's score matters far less than the system around it: keeping costs low, staying diversified, and giving compounding time to work. Treat VRTX's reading as a single input, not a verdict, and compare it against other Healthcare names rather than in isolation. The math always wins — a low-cost, broadly diversified portfolio held for years reliably beats reacting to any one score, including this one.
Commission-free ISAs & general accounts. Not a recommendation — compare fees and features yourself.
Some links are affiliate links — we may earn a commission at no extra cost to you. This never affects our analysis.
Vertex Pharmaceuticals (VRTX) — frequently asked
Is the KC Score a buy or sell signal?
No. It is an educational, rules-based description of recent price behaviour — momentum, trend, range and stability. It carries no view on valuation, fundamentals or news, and nothing here is financial advice. Your capital is at risk.
What data is the score based on?
Roughly the last twelve months of daily closing prices from public market data. The same transparent formula is applied to every stock, so scores are comparable across the site.
How often does it update?
Prices and the score refresh hourly, automatically. You may see a slightly different reading later in the day as new prices come in.
Hold VRTX? See what your whole portfolio says about you.
AlphaScore reads your real trade history and names your investor type — your edge, your blind spots, your next moves. Your statement never leaves your device. Free.